Transaction DateRecipientSharesTypePriceValue
9th February 2021Capital Viii, Llc Vivo1,933,185Conversion of derivative$0.00
9th February 2021Capital Viii, Llc Vivo266,948Conversion of derivative$0.00
9th February 2021Capital Viii, Llc Vivo17,711Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.07$1,239.77
9th February 2021Capital Viii, Llc Vivo103,372Open or private purchase$17.00$1,757,324.00
9th February 2021Capital Viii, Llc Vivo357,353Open or private purchase$17.00$6,075,001.00
9th February 2021Capital Viii, Llc Vivo472,296Conversion of derivative$0.00
9th February 2021Capital Viii, Llc Vivo1,092,080Conversion of derivative$0.00
9th February 2021Capital Viii, Llc Vivo62Open or private sale$20.00$1,240.00
9th February 2021Capital Viii, Llc Vivo944,056Conversion of derivative$0.00
9th February 2021Capital Viii, Llc Vivo14,275Open or private purchase$17.00$242,675.00
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen Betz in 2008.


Ticker: CRNX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1658247
Employees: 68
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals